@misc{9241471,
  abstract     = {{The need for development of novel drugs towards the treatment of neurodegenerative disease such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and cancer is ever-pressing, especially within aging populations. Designing an effective drug towards these normally hard-to-treat conditions requires careful balance between uptake, solubility, and blood-brain-barrier (BBB) permeability, while still retaining high affinity. Upregulation of the carbohydrate-binding protein galectin-3 (gal-3) has a proven correlation to inflammation in the central nervous system (CNS), AD, PD, and cancer, yet no therapeutics have made it past clinical trials. On the current market, macrocycles are a severely underrepresented group of compounds, showing great promise towards fulfilling the outlined criteria.
	This work concerns the synthesis of a sulfide-analogue to a target compound previously synthesized and evaluated by the group, a galactose-based macrocycle towards the inhibition of gal-3 for glycomimetic treatment of medical conditions in the CNS.
	Following a synthetic route not optimized for the sulfide-analogue, previously established by the group, the formation of the target compound was verified through nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography mass spectrometry (LC-MS) analysis, but full characterization could not be carried out. From the starting point of acetylated 4-azido galactose, this work resulted in the isolation and characterization of 3 novel compounds. However, further optimization is necessary to isolate the target compound and conduct biophysical evaluation to assess its effectiveness in comparison to those previously evaluated by the group. This work outlines a potential synthetic route towards a novel sulfide-analogue of previously isolated gal-3 inhibitors.}},
  author       = {{Almqvist, Olle}},
  language     = {{eng}},
  note         = {{Student Paper}},
  title        = {{Macrocyclic glycomimetic towards galectin-3 inhibition}},
  year         = {{2026}},
}